Harbor Capital Advisors’s Dianthus Therapeutics DNTH Stock Holding History

Harbor Capital Advisors’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,466	Closed	-$127K	–	500
2023 Q2	$127K	Buy	10,466 +957	+10%	+$10.9K	0.03%	409
2023 Q1	$121K	Sell	9,509 -548	-5%	-$6.07K	0.03%	233
2022 Q4	$63.6K	Sell	10,057 -215	-2%	-$3.81K	0.06%	156
2022 Q3	$232K	Buy	10,272 +315	+3%	+$8.62K	0.21%	80
2022 Q2	$191K	Buy	9,957 +482	+5%	+$11.9K	0.15%	82
2022 Q1	$440K	Sell	9,475 -1,883	-17%	-$103K	0.21%	81
2021 Q4	$805K	Buy	+11,358	New	+$1.14M	0.29%	82

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Harbor Capital Advisors's DNTH Position: Q3 2023 in Review

Harbor Capital Advisors sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 10,466 shares — an estimated $127K sold.

Harbor Capital Advisors first reported a position in DNTH in Q4 2021 and held it in 7 quarters. The position peaked at $805K in Q4 2021. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

Harbor Capital Advisors reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
Harbor Capital Advisors sold 10,466 Dianthus Therapeutics shares in Q3 2023, an estimated $127K.
Harbor Capital Advisors first reported a position in Dianthus Therapeutics in Q4 2021 and held it in 7 quarters.
Harbor Capital Advisors's Dianthus Therapeutics position peaked at $805K in Q4 2021.
30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Harbor Capital Advisors's 13F filing for Q3 2023, filed 20 Oct 2023.